CKD in Cats: IRIS Staging & Treatment at Every Stage
TL;DR
- Chronic kidney disease (CKD) affects up to 30–40% of cats over age 15 and is staged I–IV using the International Renal Interest Society (IRIS) system based on creatinine, SDMA, proteinuria, and blood pressure.
- Renal diets with restricted phosphorus and protein are the single intervention with the strongest survival benefit — introduce no later than IRIS Stage 2.
- Benazepril (0.5–1.0 mg/kg PO q24h) or telmisartan (2 mg/kg PO q24h) reduces proteinuria and may slow progression in proteinuric cats.
- Stage 3–4 management adds phosphate binders, maropitant for nausea, subcutaneous fluids, and erythropoiesis-stimulating agents when indicated.
- Early detection and staged intervention can extend survival by months to years — regular screening in cats ≥7 years is essential.
What Is Feline CKD and Why Does It Matter?
Chronic kidney disease in cats is a progressive, irreversible loss of functional nephrons resulting in declining glomerular filtration rate (GFR), impaired waste excretion, and disrupted fluid-electrolyte homeostasis. It is the most common metabolic disease in older cats and a leading cause of feline mortality.
The pathology typically involves chronic tubulointerstitial nephritis, though the initiating cause is often unknown. Unlike acute kidney injury (AKI), CKD develops over months to years, and clinical signs — polyuria, polydipsia, weight loss, decreased appetite — may not appear until 65–75% of nephron function is already lost.
The chronic kidney disease cats treatment stages framework developed by IRIS provides a standardized approach to diagnosis, monitoring, and therapy that has become the global standard in veterinary nephrology. The IRIS classification, updated in 2023, guides clinicians on when to initiate specific interventions, making it an indispensable tool for managing feline CKD.
Epidemiology highlights:
- Prevalence increases with age: approximately 30–40% of cats ≥15 years
- No strong breed predisposition, though Maine Coons, Abyssinians, Siamese, Russian Blues, and Burmese may carry higher risk
- Often concurrent with hyperthyroidism, hypertension, or both — complicating diagnosis and management
IRIS Staging: The Foundation of CKD Management
The IRIS staging system classifies feline CKD into four stages based on fasting blood creatinine and/or symmetric dimethylarginine (SDMA), then substages by proteinuria (urine protein-to-creatinine ratio, UPC) and blood pressure. Staging should be performed on stable, well-hydrated patients using at least two measurements taken 2–4 weeks apart.
IRIS Staging Criteria (2023 Update)
| IRIS Stage | Creatinine (mg/dL) | Creatinine (µmol/L) | SDMA (µg/dL) | Clinical Description |
|---|---|---|---|---|
| 1 | < 1.6 | < 140 | < 18 | Non-azotemic; CKD identified by other markers (imaging, persistent renal proteinuria, abnormal renal palpation, SDMA trend) |
| 2 | 1.6–2.8 | 140–250 | 18–25 | Mild renal azotemia; often subclinical or mild polyuria/polydipsia |
| 3 | 2.9–5.0 | 251–440 | 26–38 | Moderate renal azotemia; progressive clinical signs (weight loss, decreased appetite, vomiting) |
| 4 | > 5.0 | > 440 | > 38 | Severe renal azotemia; risk of uremic crisis, systemic complications |
Substaging by Proteinuria and Blood Pressure
| Substage | UPC Value | Blood Pressure (mmHg systolic) | Risk Classification |
|---|---|---|---|
| Non-proteinuric | < 0.2 | < 140 | Normotensive, minimal risk |
| Borderline proteinuric | 0.2–0.4 | 140–159 | Pre-hypertensive, low risk |
| Proteinuric | > 0.4 | 160–179 | Hypertensive, moderate risk — target organ damage possible |
| — | — | ≥ 180 | Severely hypertensive, high risk — immediate intervention |
Key points on SDMA: SDMA is a biomarker of GFR that may increase earlier than creatinine — sometimes when only ~25–40% of function is lost. The 2023 IRIS guidelines recommend using SDMA alongside creatinine, with SDMA potentially prompting upstaging if persistently elevated above the reference range for a given IRIS stage. However, SDMA should not be used in isolation; it must be interpreted alongside creatinine, urinalysis, and clinical context.
Stage-Specific Treatment: A Layered Approach
Management of feline CKD is cumulative — each stage builds upon the interventions of the previous stage. The following framework reflects IRIS 2023 recommendations and ISFM consensus guidelines.
IRIS Stage 1: Early Detection and Prevention
At this stage, renal disease is identified before azotemia develops. Diagnosis may rely on:
- Persistently elevated SDMA with normal creatinine
- Abnormal renal imaging (small, irregular kidneys; loss of corticomedullary distinction)
- Persistent renal proteinuria (UPC > 0.4)
Interventions:
- Identify and treat underlying causes (pyelonephritis, ureterolithiasis, lymphoma)
- Ensure adequate hydration — encourage water intake via wet food, water fountains
- Monitor blood pressure and treat if systolic BP ≥ 160 mmHg (amlodipine 0.125–0.25 mg/kg PO q24h)
- Address proteinuria if UPC persistently > 0.4 with benazepril or telmisartan
- Avoid nephrotoxins — NSAIDs (meloxicam at repeated doses), aminoglycosides, ethylene glycol exposure
- Screen for concurrent disease — hyperthyroidism can mask CKD by maintaining GFR through hyperfiltration
- Recheck every 3–6 months with creatinine, SDMA, UPC, blood pressure, and urinalysis
IRIS Stage 2: The Renal Diet Transition
Stage 2 is the critical window for dietary intervention — the single most impactful treatment for feline CKD.
Interventions (all Stage 1 measures plus):
- Renal diet — phosphorus-restricted (target plasma phosphorus < 4.5 mg/dL [< 1.45 mmol/L]), moderately protein-restricted, supplemented with omega-3 fatty acids and potassium. Transition gradually over 7–14 days.
- Phosphate binders if dietary phosphorus restriction alone fails to achieve target — aluminium hydroxide (30–90 mg/kg/day PO divided with meals) or lanthanum carbonate
- Potassium supplementation if hypokalaemia detected — potassium gluconate 2–6 mEq/cat/day PO
- Anti-proteinuric therapy — benazepril (0.5–1.0 mg/kg PO q24h) or telmisartan (2 mg/kg PO q24h) for cats with UPC > 0.4
- Recheck every 3–4 months
The evidence for renal diets is robust. A landmark study by Ross et al. (2006) demonstrated that cats with Stage 2–3 CKD fed a renal diet had a median survival of 633 days versus 264 days for those maintained on standard diets — a survival benefit exceeding two-fold. This remains among the strongest evidence-based interventions in veterinary internal medicine.
IRIS Stage 3: Multimodal Management
Clinical signs become more prominent. Cats often show significant weight loss, intermittent vomiting, and reduced appetite.
Interventions (all prior measures plus):
- Phosphate binders — nearly always required; target plasma phosphorus < 5.0 mg/dL (< 1.61 mmol/L)
- Anti-nausea therapy — maropitant citrate (Cerenia) 1 mg/kg PO or SC q24h for acute episodes; mirtazapine 1.88 mg/cat PO q48h or transdermal (Mirataz) 2 mg/cat applied to inner pinna q24h as appetite stimulant
- Subcutaneous (SC) fluid therapy — lactated Ringer's solution or 0.9% NaCl, typically 75–150 mL q24–72h depending on hydration status and owner capability
- Antihypertensive escalation — amlodipine 0.125–0.25 mg/kg PO q24h, titrate to systolic BP < 160 mmHg; consider adding benazepril if proteinuria persists
- Calcitriol — 1.5–3.5 ng/kg PO q24h may be considered for cats with ionized calcium within normal range but elevated PTH; controversial and requires close calcium monitoring
- Recheck every 2–3 months — include packed cell volume (PCV), phosphorus, potassium, bicarbonate, and blood pressure
IRIS Stage 4: Advanced CKD and Palliative Care
Stage 4 represents severe kidney failure with high risk of uremic crisis. Treatment focuses on quality of life.
Interventions (all prior measures plus):
- Intensified SC fluid therapy — daily administration often necessary; volumes of 100–150 mL/day are common
- Erythropoiesis-stimulating agents (ESAs) — for non-regenerative anaemia with PCV < 20%: darbepoetin alfa 1 µg/kg SC once weekly, adjusting frequency based on PCV response. Iron supplementation (iron dextran 50 mg/cat IM, repeated as needed) should accompany ESA use
- Metabolic acidosis management — sodium bicarbonate 8–12 mg/kg PO q8–12h if venous bicarbonate < 16 mEq/L
- Anti-nausea and gastric protection — maropitant as above; omeprazole 1 mg/kg PO q24h or famotidine 1–2 mg/kg PO q12–24h if gastric ulceration suspected
- Phosphate binder intensification — target plasma phosphorus < 6.0 mg/dL (< 1.93 mmol/L); sucralfate 0.25–0.5 g/cat PO q8–12h if oral ulceration present
- Appetite management — mirtazapine; consider enteral feeding via nasoesophageal or oesophagostomy tube for prolonged anorexia
- Palliative care discussions — quality-of-life assessment tools (e.g., the HHHHHMM scale) help guide decisions about humane euthanasia
- Recheck every 2–4 weeks or as clinical status dictates
Key Medications: Dosing and Practical Guidance
The following table consolidates stage-specific pharmacotherapy for feline CKD.
| Medication | Dose | Route | Frequency | Primary Indication | IRIS Stage |
|---|---|---|---|---|---|
| Benazepril (Fortekor) | 0.5–1.0 mg/kg | PO | q24h | Proteinuria (UPC > 0.4), renoprotection | 1–4 |
| Telmisartan (Semintra) | 2 mg/kg | PO | q24h | Proteinuria, alternative to benazepril | 1–4 |
| Amlodipine (Amodip) | 0.125–0.25 mg/kg | PO | q24h | Systemic hypertension | 1–4 |
| Aluminium hydroxide | 30–90 mg/kg/day | PO | Divided with meals | Hyperphosphataemia | 2–4 |
| Maropitant (Cerenia) | 1 mg/kg | PO/SC | q24h (up to 5 days continuous) | Nausea, vomiting | 3–4 |
| Mirtazapine (oral) | 1.88 mg/cat | PO | q48h | Appetite stimulation | 2–4 |
| Mirtazapine (transdermal, Mirataz) | 2 mg/cat | Topical (pinna) | q24h | Appetite stimulation | 2–4 |
| Darbepoetin alfa | 1 µg/kg | SC | q7 days initially | Non-regenerative anaemia (PCV < 20%) | 3–4 |
| Potassium gluconate | 2–6 mEq/cat/day | PO | Divided q12h | Hypokalaemia | 2–4 |
| Sodium bicarbonate | 8–12 mg/kg | PO | q8–12h | Metabolic acidosis (HCO₃⁻ < 16) | 3–4 |
| Calcitriol | 1.5–3.5 ng/kg | PO | q24h | Renal secondary hyperparathyroidism | 3–4 |
| SC fluids (LRS/NaCl) | 75–150 mL/cat | SC | q24–72h | Dehydration support | 3–4 |
Practical notes:
- Benazepril vs. telmisartan: Both are effective anti-proteinuric agents. Telmisartan (an angiotensin II receptor blocker) is approved for feline CKD by the European Medicines Agency and has the advantage of a palatable oral solution. Benazepril (an ACE inhibitor) has a longer track record. Do not combine ACE inhibitors with ARBs in cats — the risk of hypotension and acute-on-chronic renal decompensation outweighs potential benefits, and evidence for dual blockade in cats is lacking.
- Amlodipine is the first-line antihypertensive in cats. Start at the lower dose and titrate to effect. Recheck blood pressure within 5–7 days of dose adjustment.
- Mirtazapine dosing in CKD cats must account for reduced clearance — hence the reduced frequency (q48h orally) compared to healthy cats.
Side Effects and Monitoring
Monitoring Schedule by Stage
| Parameter | Stage 1–2 | Stage 3 | Stage 4 |
|---|---|---|---|
| Creatinine, BUN, SDMA | q3–6 months | q2–3 months | q2–4 weeks |
| Phosphorus, calcium, PTH | q6 months | q2–3 months | q2–4 weeks |
| Potassium, bicarbonate | q6 months | q3 months | q2–4 weeks |
| UPC | q3–6 months | q3 months | Monthly |
| Blood pressure | q3–6 months | q2–3 months | q2–4 weeks |
| PCV/haematocrit | q6 months | q3 months | q2–4 weeks |
| Body weight, BCS | Every visit | Every visit | Every visit |
Drug-Specific Adverse Effects
- Benazepril/telmisartan: Hypotension, transient creatinine elevation (up to 30% increase may be tolerable if cat remains clinically well), hyperkalaemia. Recheck creatinine and potassium 7–14 days after initiating therapy.
- Amlodipine: Rarely — tachycardia, reduced appetite. Generally well tolerated in cats.
- Aluminium hydroxide: Constipation; long-term aluminium accumulation is theoretically possible but clinically rare in cats.
- Darbepoetin alfa: Anti-erythropoietin antibody formation — can cause pure red cell aplasia, a devastating and irreversible complication. Monitor PCV closely; if PCV drops paradoxically during ESA therapy, discontinue immediately. This risk makes ESA therapy a last-resort intervention reserved for significant, symptomatic anaemia.
- Maropitant: Transient pain at SC injection site; generally well tolerated orally.
- Calcitriol: Hypercalcaemia — requires regular ionized calcium monitoring. Discontinue if ionized calcium exceeds reference range.
Cat-specific toxicity warning: Cats are exceptionally sensitive to NSAID nephrotoxicity. Even short courses of meloxicam at standard doses can precipitate acute decompensation in CKD cats. Repeated NSAID dosing is contraindicated in feline CKD. If analgesia is required, consider buprenorphine (0.01–0.03 mg/kg buccal/SC q6–8h) or gabapentin (5–10 mg/kg PO q12h) as safer alternatives.
Life Expectancy by IRIS Stage
Prognosis in feline CKD varies widely depending on stage at diagnosis, response to treatment, concurrent disease, and individual variation. The following estimates draw from published survival data and should be communicated to owners with appropriate caveats.
| IRIS Stage | Median Survival (approximate) | Key Prognostic Factors |
|---|---|---|
| 1 | > 3 years (often years of stable disease) | Proteinuria status, blood pressure control |
| 2 | ~2–3 years with dietary management | Compliance with renal diet, phosphorus control |
| 3 | ~1–2 years | Rate of creatinine progression, appetite maintenance, anaemia severity |
| 4 | Weeks to months (median ~3–6 months) | Severity of uraemia, response to fluid therapy, quality of life |
Factors associated with shorter survival:
- Persistent proteinuria (UPC > 0.4)
- Refractory hypertension
- Progressive weight loss despite intervention
- Non-regenerative anaemia unresponsive to ESAs
- Concurrent hyperthyroidism (when treated, GFR may unmask advanced CKD)
- Elevated phosphorus refractory to treatment
- Rate of creatinine/SDMA increase over time (slope of decline more predictive than single values)
Factors associated with longer survival:
- Early-stage diagnosis with dietary intervention
- Stable creatinine trajectory
- Good owner compliance with home fluid therapy and medications
- Maintained body weight and appetite
Special Populations
CKD and Concurrent Hyperthyroidism
Hyperthyroidism increases GFR through hyperdynamic circulation, which can mask underlying CKD. When hyperthyroidism is treated (methimazole, radioiodine, thyroidectomy), GFR may fall precipitously, unmasking azotemia. The ISFM recommends:
- Stabilise with methimazole (thiamazole) 1.25–2.5 mg/cat PO q12h before definitive therapy
- Reassess renal values after achieving euthyroidism (4–6 weeks)
- If creatinine rises above Stage 2 thresholds on methimazole, accept mild hyperthyroidism to preserve renal perfusion — a "permissive hyperthyroidism" strategy
CKD in Young Cats
CKD in cats under 7 years is uncommon and warrants investigation for specific causes: congenital/familial disease (polycystic kidney disease in Persians, renal amyloidosis in Abyssinians/Siamese), prior AKI, chronic pyelonephritis, or FIP-associated nephritis. Breed-specific genetic testing and renal biopsy may be indicated.
Diabetic Cats with CKD
Concurrent diabetes mellitus and CKD requires careful balancing. Renal diets are phosphorus-restricted but may contain more fat, which can complicate glycaemic control. Work with the owner to find a diet that addresses both conditions. Monitor fructosamine alongside renal parameters.
Red Flags — When to Seek Immediate Veterinary Care
Owners of cats with diagnosed CKD should seek urgent veterinary attention if any of the following occur:
- Complete anorexia lasting > 24 hours
- Persistent vomiting not responsive to maropitant
- Sudden weakness, collapse, or ataxia — possible severe hypokalaemia or hypertension-related event
- Oral ulceration or "ammonia" breath — signs of severe uraemia
- Acute blindness — hypertensive retinopathy with retinal detachment (veterinary emergency — amlodipine should be started immediately)
- Sudden increase in lethargy with pale mucous membranes — possible severe anaemia
- Seizures or altered consciousness — may indicate uremic encephalopathy or severe hypertension
- Significant change in urine output — sudden oliguria or anuria may indicate acute-on-chronic decompensation or urinary obstruction
Frequently Asked Questions
Q: Can CKD in cats be reversed? No. CKD involves irreversible structural damage to the kidneys. Treatment aims to slow progression, manage clinical signs, and maintain quality of life — not to restore lost function. However, cats can live well for extended periods with appropriate management.
Q: When should I start a kidney diet? No later than IRIS Stage 2. Evidence shows the greatest survival benefit when renal diets are introduced at Stage 2. Some clinicians consider early transition for Stage 1 cats with documented progressive disease, though this remains a matter of clinical judgement. The key challenge is acceptance — many cats resist dietary change, so gradual transition over 7–14 days (or longer) is essential.
Q: Is benazepril or telmisartan better for my cat? Both are effective anti-proteinuric agents. Telmisartan has the advantage of being formulated as a palatable oral liquid (Semintra), which many cats accept more readily than tablets. Benazepril has more extensive long-term safety data. Choice often depends on ease of administration, availability, and the cat's tolerance. They should not be used together.
Q: How do I give subcutaneous fluids at home? Your veterinarian will demonstrate the technique and prescribe appropriate fluids (usually lactated Ringer's solution). A standard protocol involves inserting an 18–20 gauge needle into the loose skin between the shoulder blades and allowing the prescribed volume (typically 75–150 mL) to flow by gravity. Most cats tolerate this well, and many owners become proficient quickly. Warm fluids to body temperature for comfort.
Q: Will my cat be in pain? CKD itself is not typically painful, though associated conditions — oral ulceration, ureterolithiasis, dehydration-related muscle cramping — can cause discomfort. Nausea is a significant welfare concern in Stage 3–4 cats and should be treated proactively with maropitant and appetite stimulants.
Q: How long can a cat live with Stage 3 CKD? With diligent management — renal diet, phosphate binders, fluid therapy, and regular monitoring — many Stage 3 cats live 1–2 years or longer. Some cats remain remarkably stable for extended periods, while others progress more rapidly. The rate of creatinine increase over time is a better predictor than any single value.
Q: Should I stop benazepril if my cat's creatinine goes up? A mild increase in creatinine (up to ~30%) after starting benazepril or telmisartan is expected and generally acceptable — it reflects reduced glomerular hyperfiltration, which is the therapeutic goal. However, if creatinine rises substantially, the cat becomes dehydrated, or shows clinical deterioration, the drug should be reduced or discontinued and the cat reassessed.
Q: Is there a role for stem cell therapy or kidney transplants? Feline renal transplantation is technically possible and performed at a small number of specialist centres, but it carries significant ethical and medical considerations — including the requirement for a donor cat and lifelong immunosuppression (ciclosporin). Stem cell therapy for feline CKD remains investigational with limited published evidence of efficacy. Neither is considered standard of care.
References
-
International Renal Interest Society (IRIS). IRIS Staging of CKD (modified 2023). IRIS Staging Guidelines
-
Sparkes AH, Caney S, Chalhoub S, et al. ISFM Consensus Guidelines on the Diagnosis and Management of Feline Chronic Kidney Disease. J Feline Med Surg. 2016;18(3):219–239. PMID: 26936494
-
Ross SJ, Osborne CA, Kirk CA, et al. Clinical evaluation of dietary modification for treatment of spontaneous chronic kidney disease in cats. J Am Vet Med Assoc. 2006;229(6):949–957. PMID: 16978113
-
King JN, Gunn-Moore DA, Tasker S, et al. Tolerability and efficacy of benazepril in cats with chronic kidney disease. J Vet Intern Med. 2006;20(5):1054–1064. PMID: 17063696
-
Sent U, Gössl R, Elliott J, et al. Comparison of efficacy of long-term oral treatment with telmisartan and benazepril in cats with chronic kidney disease. J Vet Intern Med. 2015;29(6):1479–1487. PMID: 26365691
-
European Medicines Agency (EMA). Semintra (telmisartan): EPAR Product Information. 2013 (updated). EMA — Semintra
-
Quimby JM, Lunn KF. Mirtazapine as an appetite stimulant and anti-emetic in cats with chronic kidney disease: a masked placebo-controlled crossover clinical trial. Vet J. 2013;197(3):651–655. PMID: 23838205
-
Chalhoub S, Langston CE, Eatroff A. Anemia of renal disease: what it is, what to do and what's new. J Feline Med Surg. 2011;13(9):629–640. PMID: 21872791
-
Taylor SS, Sparkes AH, Briscoe K, et al. ISFM Consensus Guidelines on the Diagnosis and Management of Hypertension in Cats. J Feline Med Surg. 2017;19(3):288–303. PMID: 28245723
-
Boyd LM, Langston C, Thompson K, et al. Survival in cats with naturally occurring chronic kidney disease (2000–2002). J Vet Intern Med. 2008;22(5):1111–1117. PMID: 18691369
About the Author
Dr. Stanislav Ozarchuk, PharmD, is a clinical pharmacist with 15 years of experience in drug safety evaluation, pharmacotherapy, and medical writing. He serves as a senior contributor to PillsCard.com, where he translates complex pharmaceutical and clinical evidence into accessible, evidence-based guides for patients, caregivers, and healthcare professionals. Dr. Ozarchuk's work emphasizes guideline-concordant therapy, comparative pharmacology, and real-world medication safety across human and veterinary medicine.
Medical Disclaimer
This article is intended for educational and informational purposes only and does not constitute veterinary medical advice, diagnosis, or treatment. The information presented reflects published guidelines and peer-reviewed literature available at the time of writing, but veterinary medicine evolves continuously. Always consult a licensed veterinarian before starting, changing, or discontinuing any medication or treatment for your cat. Individual cats may respond differently to therapies, and treatment decisions must account for the specific clinical circumstances of each patient. PillsCard.com and the author assume no liability for actions taken based on the content of this article.